CXCR4 Silencing Inhibits Invasion and Migration of Human Laryngeal Cancer Hep-2 Cells

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2015 Aug 12

PMID 26261502

Citations 6

Authors

Juntao Niu

Yongwang Huang

Lun Zhang

Affiliations

Soon will be listed here.

Abstract

CXCR4 has been reported in various types of human cancer, which is associated with cancer progression and metastasis. However, the investigation of CXCR4 in laryngeal cancer is extremely rare. In the present study, we used lentivirus-mediated shRNA targeting CXCR4 to silenced CXCR4 expression in Hep-2 cells and evaluated the effect of long-term suppression of CXCR4 on Hep-2 growth and metastasis. The Cell proliferation was analyzed by MTS assay, and the invasion and metastasis potentials were analyzed using wound healing and transwell assays, respectively. Our results showed that lentivirus-mediated shRNA effectively infected Hep-2 cells and suppressed CXCR4 expression, and inhibited cell growth of Hep-2 cells. Cell invasion and apoptosis were decreased concomitantly with the reduction in CXCR4 protein expression. Further analysis revealed that CXCR4 silencing caused the reducion of CXCR4, CXCL12, TIMP2, VEGF and MMP9, and the phosphorylation levels of IκB, AKT and MAPK, and also decreased the activity of NF-κB. These results suggested that knockdown of CXCR4 inhibits the invasion and metastasis of Hep-2 through PI3K/AKT and MAPK signaling pathways, by decreasing NF-κB activities to down-regulate VEGF, TIMP-2 and MMP-9 expression. These data demonstrate that the inhibition of CXCR4 may be an effective interventional therapeutic strategy in laryngeal cancer.

Citing Articles

Integrated Single-Cell RNA-seq and ATAC-seq Reveals Heterogeneous Differentiation of CD4 Naive T Cell Subsets is Associated with Response to Antidepressant Treatment in Major Depressive Disorder.

Sun Z, Zhang B, Zhou J, Luo Y, Zhu X, Wang Y Adv Sci (Weinh). 2024; 11(30):e2308393.

PMID: 38867657 PMC: 11321657. DOI: 10.1002/advs.202308393.

Research Progress of CXCR4-Targeting Radioligands for Oncologic Imaging.

Wang Y, Gao F Korean J Radiol. 2023; 24(9):871-889.

PMID: 37634642 PMC: 10462898. DOI: 10.3348/kjr.2023.0091.

MicroRNA-9 inhibits growth and invasion of head and neck cancer cells and is a predictive biomarker of response to plerixafor, an inhibitor of its target CXCR4.

Hersi H, Raulf N, Gaken J, Folarin N, Tavassoli M Mol Oncol. 2018; 12(12):2023-2041.

PMID: 29959873 PMC: 6275261. DOI: 10.1002/1878-0261.12352.

lncRNA-NKILA/NF-κB feedback loop modulates laryngeal cancer cell proliferation, invasion, and radioresistance.

Yang T, Li S, Liu J, Yin D, Yang X, Tang Q Cancer Med. 2018; 7(5):2048-2063.

PMID: 29573243 PMC: 5943486. DOI: 10.1002/cam4.1405.

RING finger protein 113A regulates C-X-C chemokine receptor type 4 stability and signaling.

Lear T, Dunn S, McKelvey A, Mir A, Evankovich J, Chen B Am J Physiol Cell Physiol. 2017; 313(5):C584-C592.

PMID: 28978524 PMC: 5792167. DOI: 10.1152/ajpcell.00193.2017.

References

Luo H, Wang Z, Sheng Y, Zhang Q, Yan J, Hou J . MiR-139 targets CXCR4 and inhibits the proliferation and metastasis of laryngeal squamous carcinoma cells. Med Oncol. 2013; 31(1):789. DOI: 10.1007/s12032-013-0789-z. View

Liu D, Guo H, Li Y, Xu X, Yang K, Bai Y . Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS One. 2012; 7(2):e31251. PMC: 3279370. DOI: 10.1371/journal.pone.0031251. View

Zhu Y, Yang P, Zhang X, Zhang L, Cui G, Wang Q . The effect and mechanism of CXCR4 silencing on metastasis suppression of human glioma U87 cell line. Anat Rec (Hoboken). 2013; 296(12):1857-64. DOI: 10.1002/ar.22825. View

Wang Q, Diao X, Sun J, Chen Z . Regulation of VEGF, MMP-9 and metastasis by CXCR4 in a prostate cancer cell line. Cell Biol Int. 2011; 35(9):897-904. DOI: 10.1042/CBI20100744. View

Hao L, Zhang C, Qiu Y, Wang L, Luo Y, Jin M . Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Lett. 2007; 253(1):34-42. DOI: 10.1016/j.canlet.2007.01.005. View

colovic Z, Pesutic-Pisac V, Poljak N, Racic G, Cikojevic D, Kontic M . Expression of matrix metalloproteinase-9 in patients with squamous cell carcinoma of the larynx. Coll Antropol. 2013; 37(1):151-5. View

Belcher R, Hayes K, Fedewa S, Chen A . Current treatment of head and neck squamous cell cancer. J Surg Oncol. 2014; 110(5):551-74. DOI: 10.1002/jso.23724. View

Ferlito A, Haigentz Jr M, Bradley P, Suarez C, Strojan P, Wolf G . Causes of death of patients with laryngeal cancer. Eur Arch Otorhinolaryngol. 2013; 271(3):425-34. DOI: 10.1007/s00405-013-2478-0. View

Lu F, Liu L, Yu D, Li X, Zhou Q, Liu S . Therapeutic effect of Rhizoma Dioscoreae Nipponicae on gouty arthritis based on the SDF-1/CXCR 4 and p38 MAPK pathway: an in vivo and in vitro study. Phytother Res. 2013; 28(2):280-8. DOI: 10.1002/ptr.4997. View

10.

Nayak T, Hong H, Zhang Y, Cai W . Multimodality imaging of CXCR4 in cancer: current status towards clinical translation. Curr Mol Med. 2013; 13(10):1538-48. PMC: 3838476. DOI: 10.2174/1566524013666131111121325. View

11.

Nagasawa T . CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. J Mol Med (Berl). 2014; 92(5):433-9. DOI: 10.1007/s00109-014-1123-8. View

12.

Wang Z, Chen Y, Li X, Xu L, Ma W, Chang L . Expression of VEGF-C/VEGFR-3 in human laryngeal squamous cell carcinomas and its significance for lymphatic metastasis. Asian Pac J Cancer Prev. 2012; 13(1):27-31. DOI: 10.7314/apjcp.2012.13.1.027. View

13.

Genden E, Ferlito A, Silver C, Jacobson A, Werner J, Suarez C . Evolution of the management of laryngeal cancer. Oral Oncol. 2006; 43(5):431-9. DOI: 10.1016/j.oraloncology.2006.08.007. View

14.

Homer J, Greenman J, Stafford N . The expression of vascular endothelial growth factor (VEGF) and VEGF-C in early laryngeal cancer: relationship with radioresistance. Clin Otolaryngol Allied Sci. 2002; 26(6):498-504. DOI: 10.1046/j.1365-2273.2001.00512.x. View

15.

Wei L, Zhang B, Cao W, Xing H, Yu X, Zhu D . Inhibition of CXCL12/CXCR4 suppresses pulmonary arterial smooth muscle cell proliferation and cell cycle progression via PI3K/Akt pathway under hypoxia. J Recept Signal Transduct Res. 2014; 35(4):329-39. DOI: 10.3109/10799893.2014.984308. View

16.

Papadas T, Naxakis S, Mastronikolis N, Stathas T, Karabekos N, Tsiambas E . Determination of matrix metalloproteinase 9 (MMP-9) protein expression in laryngeal squamous cell carcinomas based on digital image analysis. J BUON. 2013; 18(4):977-81. View

17.

Cojoc M, Peitzsch C, Trautmann F, Polishchuk L, Telegeev G, Dubrovska A . Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther. 2013; 6:1347-61. PMC: 3794844. DOI: 10.2147/OTT.S36109. View

18.

Peng S, Zhang X, Paul D, Kays L, Gough W, Stewart J . Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol Cancer Ther. 2014; 14(2):480-90. DOI: 10.1158/1535-7163.MCT-14-0850. View

19.

Nakayama M, Nakayama A, van Lessen M, Yamamoto H, Hoffmann S, Drexler H . Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat Cell Biol. 2013; 15(3):249-60. PMC: 3901019. DOI: 10.1038/ncb2679. View

20.

Vokes E, Stenson K . Therapeutic options for laryngeal cancer. N Engl J Med. 2003; 349(22):2087-9. DOI: 10.1056/NEJMp038171. View